1. Home
  2. HURA vs BNED Comparison

HURA vs BNED Comparison

Compare HURA & BNED Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • HURA
  • BNED
  • Stock Information
  • Founded
  • HURA 2009
  • BNED 1965
  • Country
  • HURA United States
  • BNED United States
  • Employees
  • HURA N/A
  • BNED N/A
  • Industry
  • HURA
  • BNED Other Specialty Stores
  • Sector
  • HURA
  • BNED Consumer Discretionary
  • Exchange
  • HURA Nasdaq
  • BNED Nasdaq
  • Market Cap
  • HURA 246.9M
  • BNED 283.2M
  • IPO Year
  • HURA N/A
  • BNED N/A
  • Fundamental
  • Price
  • HURA $4.39
  • BNED $10.07
  • Analyst Decision
  • HURA
  • BNED Hold
  • Analyst Count
  • HURA 0
  • BNED 2
  • Target Price
  • HURA N/A
  • BNED $125.00
  • AVG Volume (30 Days)
  • HURA 668.3K
  • BNED 637.3K
  • Earning Date
  • HURA 02-15-2025
  • BNED 12-09-2024
  • Dividend Yield
  • HURA N/A
  • BNED N/A
  • EPS Growth
  • HURA N/A
  • BNED N/A
  • EPS
  • HURA N/A
  • BNED N/A
  • Revenue
  • HURA N/A
  • BNED $1,558,148,000.00
  • Revenue This Year
  • HURA N/A
  • BNED $5.54
  • Revenue Next Year
  • HURA N/A
  • BNED N/A
  • P/E Ratio
  • HURA N/A
  • BNED N/A
  • Revenue Growth
  • HURA N/A
  • BNED 0.24
  • 52 Week Low
  • HURA $2.84
  • BNED $6.05
  • 52 Week High
  • HURA $14.60
  • BNED $226.00
  • Technical
  • Relative Strength Index (RSI)
  • HURA N/A
  • BNED 48.57
  • Support Level
  • HURA N/A
  • BNED $11.18
  • Resistance Level
  • HURA N/A
  • BNED $12.68
  • Average True Range (ATR)
  • HURA 0.00
  • BNED 1.39
  • MACD
  • HURA 0.00
  • BNED -0.10
  • Stochastic Oscillator
  • HURA 0.00
  • BNED 16.45

About HURA TuHURA Biosciences Inc. Common Stock

TuHURA Biosciences Inc is a Phase 3 registration stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. It is preparing to initiate a single randomized placebo-controlled Phase 3 registration trial of IFx-2.0 administered as an adjunctive therapy to Keytruda (pembrolizumab) in first-line treatment for advanced or metastatic Merkel Cell Carcinoma.

About BNED Barnes & Noble Education Inc

Barnes & Noble Education Inc is an operator of bookstores in college and university campuses across the United States. The company is also engaged in providing digital education services. It operates in three reportable segments that include Retail offers existing and prospective clients the flexibility of physical, virtual, or custom store solutions, and wholesale is comprised of the wholesale and virtual retail fulfillment, and support operations of the MBS subsidiary, also Corporate Services represent unallocated shared-service costs which include corporate level expenses and other governance functions, including executive functions, such as accounting, legal, treasury, information technology, and human resources. It earns majority of the revenue from Retail segment.

Share on Social Networks: